Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C

Archives of Virology

Volumn 157, Issue 6, 2012, Pages 1113-1121

  Zeng, Yanli ^a   Li, Wei ^a   Li, Jingtao ^a   Wang, Junjie ^a   Zhou, Bin ^a   Zhang, Jian ^a   Liu, Shuwen ^a   Wu, Yingsong ^a   Hou, Jinlin ^a   Zhou, Yuanping ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CHINA; CLASSIFICATION; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETIC VARIABILITY; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TREATMENT OUTCOME; VIROLOGY;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CHINA; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RIBAVIRIN; TREATMENT OUTCOME; VIRAL PROTEINS; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 84861778066     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-012-1283-1     Document Type: Article

References (40)

1. Global Burden Of Hepatitis C Working Group (2004) Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 44: 20-29.
2. Alter MJ (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol 13: 2436-2441.
3. Marcellin P (1999) Hepatitis C: the clinical spectrum of the disease. J Hepatol 31(Suppl 1): 9-16.
4. Leone N, Rizzetto M (2005) Natural history of hepatitis C virus infection from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 51: 31-46.
5. Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85: 3173-3188.
6. Bukh J, Miller RH, Purcell RH (1995) Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15: 41-63.
7. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, Netesov S, Nishioka K, Shin IT, Simmonds P, Smith D, Stuyver L, Weiner A (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International committee on virus taxonomy. Arch Virol 143: 2493-2503.
8. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS5 region. J Gen Virol 74(11): 2391-2399.
9. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
10. Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972.
11. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580-593.
12. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH (2005) Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 75: 538-549.
13. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
14. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
15. Limaye AR, Draganov PV, Cabrera R (2011) Boceprevir for chronic HCV genotype 1 infection. N Engl J Med 365(176): 177-178.
16. Pawlotsky JM (2004) Treating hepatitis C in "difficult-to-treat" patients. N Engl J Med 351: 422-423.
17. Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE (2008) Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS ONE 3: e2123.
18. Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE (2010) Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in caucasian american and african american patients. PLoS ONE 5: e9032.
19. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE (2007) Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 81: 8211-8224.
20. Xiang X, Lu J, Dong Z, Zhou H, Tao W, Guo Q, Zhou X, Bao S, Xie Q, Zhong J (2011) Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. Infect Genet Evol 11: 382-390.
21. Liu Z, Netski DM, Mao Q, Laeyendecker O, Ticehurst JR, Wang XH, Thomas DL, Ray SC (2004) Accurate representation of the hepatitis C virus quasispecies in 5. 2-kilobase amplicons. J Clin Microbiol 42: 4223-4229.
22. Tamura K, Dudley J, Nei M, Kumar S (2007) Mega4: molecular evolutionary genetics analysis (mega) software version 4. 0. Mol Biol Evol 24: 1596-1599.
23. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
24. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FJ, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
25. Gale MJ, Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature 436: 939-945.
26. Hofmann WP, Zeuzem S, Sarrazin C (2005) Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 32: 86-91.
27. Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85: 3173-3188.
28. Pavio N, Lai MM (2003) The hepatitis C virus persistence: how to evade the immune system? J Biosci 28: 287-304.
29. Lin C, Lindenbach BD, Pragai BM, McCourt DW, Rice CM (1994) Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J Virol 68: 5063-5073.
30. Gonzalez ME, Carrasco L (2003) Viroporins. FEBS Lett 552: 28-34.
31. Ma Y, Anantpadma M, Timpe JM, Shanmugam S, Singh SM, Lemon SM, Yi M (2011) Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J Virol 85: 86-97.
32. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM (2007) Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 81: 8374-8383.
33. Kaukinen P, Sillanpaa M, Kotenko S, Lin R, Hiscott J, Melen K, Julkunen I (2006) Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virol J 3: 66.
34. Foy E, Li K, Wang C, Sumpter RJ, Ikeda M, Lemon SM, Gale MJ (2003) Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300: 1145-1148.
35. Foy E, Li K, Sumpter RJ, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale MJ (2005) Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 102: 2986-2991.
36. Aparicio E, Franco S, Parera M, Andres C, Tural C, Clotet B, Martinez MA (2011) Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. J Virol 85: 5961-5969.
37. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T (2007) Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 3: e103.
38. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 103: 7408-7413.
39. Yi M, Ma Y, Yates J, Lemon SM (2007) Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 81: 629-638.
40. Ukai K, Ishigami M, Yoshioka K, Kawabe N, Katano Y, Hayashi K, Honda T, Yano M, Goto H (2006) Mutations in carboxy-terminal part of E2 including PKR/eIF-alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load. World J Gastroenterol 12: 3722-3728.